At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer.

"Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via a profound comprehension of how investigational new drugs work," said Peter Adamson, M.D., world wide development thoughts, Oncology and Pediatric Innovation in Sanofi. "This alliance leverages MD Anderson's pragmatic approach to early phase clinical trials, their own laboratory capabilities and broad scientific expertise. This will make us to go/no-go decisions substantially faster and allow us to identify potential new combinations and signs more accurately. That helps you to save you precious time and help us expand the range of patients who might potentially benefit from our therapies."

<em>Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients. We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies."-</em>Funda Meric-Bernstam, M.D., Chair of Investigational Cancer Therapeutics

MD Anderson oversees one among the country's largest <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials">oncology clinical trial</a></span> programs, together with well-established platforms such as tissue accumulation, immune and molecular profiling, and data investigation. This infrastructure enables the thorough analysis of chemical samples taken prior to, during and after treatment to uncover valuable insights which help streamline patient decision and also quicken the identification of fresh therapy combinations and indications.

The brand new alliance also will encourage analyses in to additional indications and combinations for studies in the clinic. <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.mdanderson.org/newsroom/md-anderson-and-sanofi-announce-strategic-collaboration-to-accelerate-oncology-research-and-development.h00-159383523.html#:~:text=Sanofi%20and%20MD%20Anderson%20scientists,effects%20at%20different%20disease%20stages.">Sanofi and MD Anderson scientists</a> </span>can collaborate on civic design, employing a core group of biomarkers and assays. Joint projects additionally will apply book investigational agents developed in Sanofi to present receptor samples to acquire additional data in their effects at different disease stages.

<em>MD Anderson's expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues. The knowledge we gain in this collaboration will also deepen our shared understanding of cancers' potential vulnerabilities."-Dmitri Wiederschain, Ph.D., Global Head of Immuno-Oncology Research at Sanofi</em>

New findings, in addition to large scale molecular and phenotype datasets, will likely be applied to the style of new translational studies on selected Sanofi molecules, and also guide the choice of signals. The collaboration is expected to launch its first endeavors in the summer 2020.